Paliperidon Palmitat 3 Aylık Formülasyon Kullanan Hastaların İncelenmesi

Psikotik bozukluğu olan hastalarda oral antipsikotiklere uyum sorunları sık görülür. Uyum yönetimini desteklemek için uzun etkili enjekte edilebilir antipsikotiklerin kullanılması önerilmiştir. Bu çalışmada paliperidon palmitat 3 aylık formülasyon (PP3A) kullanan hastaların incelenmesi amaçlandı. Çalışmaya 21 hasta (8 kadın ve 13 erkek) dahil edildi. Ortalama yaş 40,90±10,98 yıl, hastalık başlangıç yaşı 18,47±3,64 yıl, paliperidon palmitat 1 aylık formülasyon kullanım süresi 12,38±14,68 ay, PP3A kullanım süresi 4,66±1,85 ay idi. Yirmi hasta şizofreni tanılıyken, bir erkek hasta şizoaffektif bozukluk tanılıydı. PP3A uzun süreli sürekli ilaç kullanımı ve takibi gerektirmediğinden uyum sorunu olan hastalarda kullanımı önemli faydalar sağlamaktadır.

Anahtar Kelimeler:

Paliperidon palmitat üç aylık uzun etkili enjeksiyon, hasta uyumu, şizofreni, şizoaffektif bozukluk

Examination of Patients Using Paliperidone Palmitate 3-Month Formulation

Adherence problems to oral antipsychotics are common in patients with psychotic disorders. The use of long-acting injectable antipsychotics has been suggested to support adherence management. This study aimed to examine the patients who used paliperidone palmitate 3-month formulation (PP3M). Twenty-one patients (8 females and 13 males) were included in the study. The mean age was 40.90±10.98 years, the age of disorder onset was 18.47±3.64 years, the duration of paliperidone palmitate once-monthly formulation use was 12.38±14.68 months, the duration of PP3M use was 4.66±1.85 months. While 20 patients were diagnosed with schizophrenia, 1 male patient was diagnosed with schizoaffective disorder. Since PP3M does not require long-term continuous drug use and follow-up, its use in patients with adherence problems provides significant benefits.

Keywords:

Paliperidone palmitate three-month long-acting injection, patient compliance, schizophrenia, schizoaffective disorder,

PDF

___

Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171-1180. DOI: 10.2147/PPA.S53795.
Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Association. 5th ed. Arlington, United States. American Psychiatric Publishing, 2013.
Lamb YN, Keating GM. Paliperidone palmitate intramuscular 3-monthly formulation: A review in schizophrenia. Drugs. 2016;76(16):1559-1566. DOI: 10.1007/s40265-016-0645-5.
Jukic V, Jakovljevic M, Filipcic I, Herceg M, Silic A, Tomljanovic T, et al. Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia. Value Health Reg Issues. 2013;2(2):181-188. DOI: 10.1016/j.vhri.2013.06.008.
Debaveye S, De Smedt D, Heirman B, Kavanagh S, Dewulf J. Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections. BMC Health Serv Res. 2019;19(1):393. DOI: 10.1186/s12913-019-4247-2.
Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25(3):238-251. DOI: 10.1093/ijnp/pyab071.